Aspisol

The main ingredient of this product is: lysine.

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), the risk of bleeding may be increased. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product may rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this product is already stable may lead to an increase in the blood drug concentration of this product and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this product when used together, the dose of this product should be increased if necessary. Long-term use of this product with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this product together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this product at the same time; when the blood concentration of salicylate is 50μg/ml, it is significantly reduced, and it is even worse when it is 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.

The main ingredients of this product are: Lysine

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), there is a risk of increasing bleeding. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this drug is already stable may lead to an increase in the blood drug concentration of this drug and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this drug when used together, the dose of this drug should be increased if necessary. Long-term use of this drug with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this drug together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this drug at the same time; when the blood concentration of salicylate is greater than 50μg/ml, it is significantly reduced, and it is even more so when it is greater than 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.

The main ingredients of this product are: Lysine

(1) When used together with any drug that can cause hypoprothrombinemia, thrombocytopenia, decreased platelet aggregation function or bleeding from gastrointestinal ulcers, there is a risk of aggravating coagulation disorders and causing bleeding. (2) When used together with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), there is a risk of increasing bleeding. (3) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in the urine and reduce the blood concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (4) Uric acidifying drugs can reduce the excretion of this product and increase its blood concentration. The addition of uricosuric drugs to patients whose blood drug concentration of this drug is already stable may lead to an increase in the blood drug concentration of this drug and an increase in toxic reactions. (5) Glucocorticoids can increase the excretion of salicylates. In order to maintain the blood drug concentration of this drug when used together, the dose of this drug should be increased if necessary. Long-term use of this drug with glucocorticoids, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. It is not recommended to use these two types of drugs at the same time. (6) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using this drug together. (7) When used together with methotrexate, it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (8) The uricosuric effect of probenecid or sulfinpyrazone can be reduced by using this drug at the same time; when the blood concentration of salicylate is greater than 50μg/ml, it is significantly reduced, and it is even more so when it is greater than 100-150μg/ml. In addition, probenecid can reduce the clearance of salicylates from the kidneys, thereby increasing the latter's blood concentration.